Hamada, Chikuma
Okusaka, Takuji
Ikari, Takaaki
Isayama, Hiroyuki
Furuse, Junji
Ishii, Hiroshi
Nakai, Yousuke
Imai, Shogo
Okamura, Shota
Article History
Received: 26 October 2016
Revised: 29 March 2017
Accepted: 12 April 2017
First Online: 4 May 2017
Competing interests
: CH has received consultancies from Taiho Pharmaceutical Co., Ltd. TO has received honoraria from Taiho Pharmaceutical Co., Ltd., Eli Lilly Japan KK, consultancies and research funding from Eli Lilly Japan KK and Taiho Pharmaceutical Co., Ltd. H Isayama has received honoraria from Taiho Pharmaceutical Co., Ltd. and Eli Lilly Japan KK, and research funding from Taiho Pharmaceutical Co., Ltd. JF has received honoraria from Taiho Pharmaceutical Co., Ltd. and Eli Lilly Japan KK, consultancies from Taiho Pharmaceutical Co., Ltd., and research funding from Taiho Pharmaceutical Co., Ltd. and Eli Lilly Japan KK H Ishii, has received honoraria from Taiho Pharmaceutical Co., Ltd. and Eli Lilly Japan KK, and research funding from Taiho Pharmaceutical Co., Ltd. The remaining authors declare no conflict of interest.